Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 6/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27730147 | 0.83 | CA12 (0.50) | MEN1KMT2ALMNATSHRMMP1 | |
| SCHEMBL25409905 | 0.81 | CA12 (0.43) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL304323 | 0.80 | MEN1 (0.32) | MEN1KMT2ACHRNB2CHRNA4CA12 | |
| SCHEMBL758863 | 0.79 | KMT2A (0.48) | MEN1KMT2ALMNATSHRMMP1 | |
| SCHEMBL16965411 | 0.79 | MEN1 (0.48) | MEN1KMT2ALMNATSHRMMP1 | |
| SCHEMBL19897293 | 0.78 | — | — | |
| SCHEMBL305824 | 0.78 | CA12 (0.47) | LMNATSHRMMP1MMP2MMP3 | |
| Hydrochloric Acid SCHEMBL27831562 | 0.77 | KMT2A (0.46) | MEN1KMT2ALMNATSHRMMP1 | |
| Ammonia Solution, Strong SCHEMBL9456471 | 0.77 | KMT2A (0.46) | MEN1KMT2ALMNATSHRMMP1 | |
| SCHEMBL27332953 | 0.76 | KMT2A (0.42) | MEN1KMT2ALMNATSHRMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022152705-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-07-21 | — | — | WO | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3405471-B1 | NEW AMMONIUM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2019-10-30 | — | — | EP | disclosed |
| US-10457689-B2 | Ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-10-29 | — | — | US | disclosed |
| US-20190031677-A1 | AMMONIUM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2019-01-31 | — | — | US | disclosed |
| EP-3405471-A1 | NEW AMMONIUM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2018-11-28 | — | — | EP | disclosed |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | disclosed |
| EP-1834947-A2 | 3-substituted amino-1H-indole-2-carboxylic acid and 3-substituted amino-benzo[B]thiophene-2carboxylic acid derivatives as interleukin-4 gene expression inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1501796-B1 | 3-(PYRIDINYL-AMINO)-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1501796-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1501797-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-15 | — | — | US | disclosed |
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003091215-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO’ B! THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERIEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091214-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | IL4, IL4I1, STAT4 | MEN1 3547/4885KMT2A 833/4885LMNA 4813/4885 |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | MEN1 2444/4885KMT2A 4768/4885LMNA 112/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | MEN1 2988/4885KMT2A 4011/4885LMNA 2434/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | MEN1 2988/4885KMT2A 4011/4885LMNA 2434/4885 |
| US-10457689-B2 | Ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | ARG1, ASS1, ATP6V1B1 | MEN1 1107/4885KMT2A 2252/4885LMNA 3168/4885 |
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | IL4, STAT4, BCL6 | MEN1 4076/4885KMT2A 598/4885LMNA 4805/4885 |
| US-20190031677-A1 | AMMONIUM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ARG1, ASS1, ATP6V1B1 | MEN1 1107/4885KMT2A 2252/4885LMNA 3168/4885 |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | IL4, STAT4, STAT6 | MEN1 4032/4885KMT2A 529/4885LMNA 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.